What this study looked at
Alpha-mannosidosis (AM) is a rare inherited disorder, caused by a deficiency of the enzyme alpha-mannosidase, that leads to progressive problems with balance, the immune system, the skeleton and thinking from early childhood. This study used a standard test of fine and gross motor skills, the Bruininks-Oseretsky test (BOT-2), to see whether enzyme replacement therapy with velmanase alfa improved movement. It drew together data from 14 adults and 19 children treated for up to four years.
Key takeaways
- Across the whole group, motor proficiency scores rose by a statistically significant 13% from the start of treatment to the last measurement.
- The improvement was concentrated in children under 18, whose scores rose by an average of 23%, whereas adults showed little change.
- Children tended to keep pace with or gain on their healthy peers, suggesting they continued to acquire new skills during treatment.
Why it matters
Continued skill development can mean greater independence and a better quality of life, and these findings point to particular benefit when treatment begins in childhood.
